<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82491">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02154048</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00019301</org_study_id>
    <nct_id>NCT02154048</nct_id>
  </id_info>
  <brief_title>Analgesic Efficacy of Perineural Dexamethasone During Supraclavicular Block for Hand Surgery</brief_title>
  <official_title>Analgesic Efficacy of Perineural Dexamethasone Added to Ropivacaine 0.5% With 1:400,000 Epinephrine During Single-injection Supraclavicular Block for Outpatient Hand Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the addition of dexamethasone prolongs
      analgesia when added to long-acting local anesthetic during single-injection supraclavicular
      block for outpatient hand surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal for pain control after surgery is to provide the best possible pain control for the
      longest period of time with the least amount of side effects.  One type of pain medication
      is called local anesthetic, which is a numbing medication that is injected in the area
      surrounding nerves to block pain.  This injection is called a nerve block.  Ropivacaine is a
      local anesthetic that is commonly used for nerve blocks and will be used in this study.  The
      effects of ropivacaine may last for 8 to 12 hours after surgery.  Recent research studies
      have shown that adding a medication called dexamethasone (a steroid) may increase the time
      that the nerve block will provide pain control. The purpose of this study is to see if
      adding dexamethasone to ropivacaine and injecting this around the nerves during a
      supraclavicular brachial plexus block increases the duration of pain relief as compared to
      both placebo control and systemic control groups.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to first analgesic dose</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Surgery, Hand</condition>
  <arm_group>
    <arm_group_label>ropivacaine + dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with 1:400,000 epinephrine and an IV preservative-free dexamethasone 8 mg injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ropivacaine + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with 1:400,000 epinephrine and an intravenous (IV) normal saline placebo injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ropivacaine + dexamethasone  + placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with both 1:400,000 epinephrine and preservative-free dexamethasone 8mg and an IV normal saline placebo injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <arm_group_label>ropivacaine + dexamethasone</arm_group_label>
    <arm_group_label>ropivacaine + placebo</arm_group_label>
    <arm_group_label>ropivacaine + dexamethasone  + placebo</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>ropivacaine + dexamethasone</arm_group_label>
    <arm_group_label>ropivacaine + dexamethasone  + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>ropivacaine + placebo</arm_group_label>
    <arm_group_label>ropivacaine + dexamethasone  + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 years of age and older

          -  Patients scheduled for elective outpatient hand surgery with same day discharge at
             the Duke Ambulatory Surgery Center

        Exclusion Criteria:

          -  Patients who refuse regional anesthesia

          -  Patients in whom peripheral nerve block is contraindicated

          -  Patients unable to sign/understand consent

          -  Patients with significant language barriers who cannot comply with data collection
             process

          -  Patients with known allergies to local anesthetics

          -  Pregnancy

          -  Chronic pain patients or patients requiring chronic opioid treatment

          -  Patients with a history of diabetes

          -  Patients with contraindication to steroid administration (allergy, chronic steroid
             use)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Melton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>May 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
